STOML3

Across TCGA pan-cancer cohorts, STOML3 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of STOML3’s most consistent transcriptional readouts.

The strongest signal is observed in stomach adenocarcinoma (STAD), where STOML3 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types STOML3 is over-expressed in tumor, although a few such as LUAD and LUSC show the opposite, repressed pattern.

STAD, LUAD, and LUSC are the cancer types where STOML3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in STOML3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
STAD	Male	All	+0.291	<.001	9	view →
LUAD	Female	III,IV	−2.017	<.001	8	view →
LUSC	All	II,III,IV	−1.627	<.001	7	view →
COAD	All	II,III,IV	+0.262	.001	6	view →
BRCA	Female	II,III,IV	−0.116	<.001	6	view →
KICH	All	All	−0.089	.001	6	view →
KIRC	All	All	+0.157	.001	4	view →
READ	Female	All	+0.628	.025	2	view →
KIRP	Female	All	+0.378	.024	1	view →
BLCA	All	III,IV	+0.081	.021	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

STOML3–STAD

Open the STAD breakdown →